heart%20failure%20-%20chronic
HEART FAILURE - CHRONIC
Heart failure is a clinical syndrome due to a structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood in order to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues.
Symptoms are caused by ventricular dysfunction secondary to abnormalities of the myocardium, pericardium, endocardium, valves, heart rhythm and conduction.
New onset heart failure refers to the first presentation of heart failure.
Transient heart failure refers to the symptomatic heart failure over a limited period of time although long-term therapy may be indicated.
Chronic heart failure is stable, worsening, or decompensated heart failure.

Pharmacotherapy

Please see the Heart Failure - Acute Disease Management Chart for information on intravenous (IV) drugs administered in the hospital/healthcare facility for emergency cases of heart failure

Control of Risk and Prevention of Cardiovascular Events

Hypertension and Dyslipidemia

  • Please see Hypertension and Dyslipidemia Disease Management Charts
  • Recommended optimal BP for HF patients with hypertension is <130/80 mmHg

Diabetes Mellitus (DM)

  • Screen for diabetes, measure fasting blood glucose, confirm diagnosis of type 2 DM
  • Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) can prevent the development of end-organ disease, cardiovascular complications and risk of heart failure (HF) in patients with diabetes and those without hypertension
  • Long-term treatment with ACE inhibitors or ARBs
  • ARBs and Empagliflozin (an SGLT2 inhibitor) decrease the incidence of hospitalizations due to HF

Atherosclerotic Disease

  • One large-scale trial showed that long-term therapy with an ACE inhibitor decreased the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with known vascular disease
  • ACE inhibitors prevent HF in patients who are at high risk of developing HF, have a history of atherosclerotic vascular disease, DM, or hypertension with associated CV risk factors

Treatment Strategy

  • The use of ACE inhibitor or ARB, beta-blocker, and mineralocorticoid receptor antagonist (MRA) is important in modifying the course of systolic HF
    • Should be considered in all patients with HF because it decreases the risk of HF hospitalization and premature death
    • They are commonly used in conjunction with a diuretic to relieve the symptoms and signs of congestion
  • A study showed that the initial HF drug therapy exerts a possible synergistic effect from the add-on drug therapy and the baseline drug therapy

ACE (ACEI)Inhibitors

  • Recommended for the prevention of HF in patients at risk of this syndrome
  • ACE inhibitors should be prescribed to all patients with decreased left ventricular ejection fraction (LVEF) of ≤40% regardless of symptoms unless contraindicated or not tolerated
  • Started as soon as HF diagnosis is made because of its modest effect on left ventricular (LV) remodelling withc delays the development of symptomatic congestive heart failure (CHF) in patients with asymptomatic LV dysfunction and those without ventricular dysfunction
  • Should only be used in patients with adequate renal function and normal serum potassium
  • If a patient has recent or current history of fluid retention, diuretics should be started prior to ACE inhibitors to ensure sodium balance, preventing peripheral and pulmonary edema

Angiotensin II Antagonists/Angiotensin Receptor Blockers (ARBs)

  • Recommended as an alternative in patients who are intolerant of ACE inhibitors due to cough or angioedema; patients should also be given a beta-blocker and an MRA
  • May also be considered in patients with systolic CHF who remain symptomatic despite receiving ACE inhibitors and a beta-blocker and are intolerant of MRA
  • Avoid use in patients with recent acute MI and decreased LVEF who are on ACE inhibitor and beta-blocker
  • Triple combination of ACE inhibitor, ARB, and mineralocorticoid receptor antagonist is not recommended due to increased risk of hyperkalemia

Angiotensin Receptor Neprilysin Inhibitor (ARNI)

  • Eg Sacubitril/Valsartan
  • Acts by inhibiting neprilysin which slows down the degradation of natriuretic peptides, bradykinin and other peptides leading to high amounts of circulating A-type natriuretic peptide and BNP resulting in diuresis, natriuresis and relaxation and anti-remodelling of the myocardium
  • Recommended as a replacement for an ACE inhibitor to further decrease morbidity and mortality in patients with HF with reduced ejection fraction (EF) who are still symptomatic despite optimal therapy with an ACE inhibitor, a beta-blocker and an MRA
  • Treatment should not be combined with ACE inhibitor or ARB or within 36 hours from the last dose of ACE inhibitor

Beta-Blockers

  • Beta-blockers are recommended in all stable HF patients with decreased LVEF, unless contraindicated or not tolerated
  • Preferred 1st-line treatment to control ventricular rate for patients in New York Heart Association (NYHA) class I-III provided they are euvolemic
  • Also used in patients with prior MI to reduce mortality, recurrent MI, and development of HF
  • May also be used to control the ventricular rate in HF patients with preserved EF and atrial fibrillation
  • Prevents ischemia and inhibit the adverse effects of the sympathetic nervous system in HF

Calcium Channel Blockers

  • Dihydropyridine calcium channel blockers may be used to treat hypertension and coronary heart disease in patients with systolic CHF
    • Have not shown survival benefits but no adverse outcomes were observed
  • Non-dihydropyridine calcium channel blockers that are negative inotropes are contraindicated in patients with systolic HF
    • However, Diltiazem is sometimes used in patients with CHF and atrial fibrillation (AF) to decrease excessive exercise-related heart rates

Digoxin

  • Digoxin may be used to slow a rapid ventricular rate in patients with symptomatic HF, LVEF ≤40%, and AF in addition to or prior to a beta-blocker
    • Recommended as the preferred second drug, in addition to a beta-blocker, to control the ventricular rate in patients with inadequate response to beta-blocker
  • May be considered to reduce the risk of HF hospitalization in patients in sinus rhythm with an EF ≤45% who are unable to tolerate a beta-blocker
    • Patient should also receive an ACE inhibitor (or ARB) and MRA (or ARB)
  • May also be used be in patients with EF ≤ 45% and persisting symptoms despite treatment with a beta-blocker, ACE inhibitor (or ARB), and MRA (or ARB)

Diuretics

  • Recommended in patients with HF and those with clinical manifestations of congestion regardless of EF
  • Start with a low dose and titrate accordingly until clinical improvement is achieved
  • Adjust dose after restoration of dry body weight to avoid risk of dehydration, hypotension, and renal dysfunction
  • Should be used in combination with an ACE inhibitor or ARB
  • Produce a more gentle and prolonged diuresis
  • Work synergistically when used in combination with loop diuretics for the treatment of resistant edema

Loop Diuretics

  • Preferred diuretic for the treatment of HF
  • Used in patients with more severe volume overload or if there is inadequate response to thiazide
    • Produce a greater fractional excretion of filtered sodium and more intense, shorter diuresis

Thiazide Diuretics

  • May be effective as a monotherapy in HF patients with mild congestion and normal renal function

Potassium-Sparing Diuretics

  • Recommended in patients with excessive potassium losses secondary to the use of loop diuretics
  • Also used in combination with thiazides for the treatment of hypertension
  • Caution is needed if a potassium-sparing diuretic is used in addition to ACE inhibitor or ARB and MRA

Combinations

  • Thiazides or Metolazone can be used in combination with loop diuretics for a synergistic effect in patients with persistent fluid retention despite high-dose loop diuretic treatment
  • Chronic daily use of these agents, especially of Metolazone, should be avoided because of the risk of electrolyte imbalance and dehydration

Hydralazine + Isosorbide Dinitrate

  • This combination is reserved in patients who cannot tolerate ACE inhibitors and ARBs, in whom these agents are contraindicated, and if no other treatment options are available
  • May be considered in patients with HF and decreased LVEF who remain symptomatic despite optimal standard therapy
  • Hydralazine and Isosorbide have complimentary dilating actions
    • Isosorbide may also inhibit abnormal myocardial and vascular growth and therefore may reduce ventricular remodeling
    • Hydralazine may interfere with the molecular mechanisms responsible for the progression of HF

Ivabradine

  • A selective sinus node I(f) channel inhibitor that is known for slowing the heart rate
  • Considered in patients with sinus rhythm suffering from angina who cannot tolerate beta-blockers or when there is treatment failure after beta-blocker therapy
  • Approved for use in patients with a heart rate of ≥75 bpm
  • May be considered to reduce the risk of HF hospitalization in patients in sinus rhythm with an LVEF ≤35%, heart rate of ≥70 bpm at rest, with persisting symptoms (NYHA class II-III) and with inadequate response to evidence-based dose of beta-blockers, ACE inhibitors (or ARB) and MRA (or ARB)

Mineralocorticoid Receptor Antagonists (MRA)/Aldosterone Antagonists

  • Spironolactone and Eplerenone block receptors that bind aldosterone and other corticosteroids, and are best characterized as MRAs
  • Recommended for patients who remain symptomatic despite treatment with ACE inhibitor and beta-blocker
    • Recommended in patients following an acute MI, with clinical heart failure manifestations or history of DM, and LVEF <40%, while receiving standard therapy
    • Treatment option for patients with HF with preserved ejection fraction (EF ≥45%, increased BNP, estimated GFR >30 mL/minute, creatinine <2.5 mg/dL, potassium <5 mEq/L) to reduce hospitalizations
  • Spironolactone is recommended for patients who remain severely symptomatic despite appropriate doses with ACE inhibitors and diuretics
  • Eplerenone is considered in patients with systolic HF who still have mild symptoms despite receiving standard therapy of ACE inhibitors and beta-blockers
  • Should only be used in patients with adequate renal function and normal serum potassium
    • Serial monitoring of serum electrolytes and renal enzymes are mandatory

Tolvaptan

  • A vasopressin V2-receptor antagonist that may be used in the short term for the treatment of resistant hypervolemic hyponatremia despite water restriction and guideline-directed medical therapy
  • Adverse effects may include thirst and dehydration

Coenzyme Q10 (CoQ10)

  • A lipid-soluble cofactor found in the mitochondrial inner membrane that has antioxidant properties and a bioenergetic role; it is predominantly located in the myocardium
  • Decrease in the myocardial levels of CoQ10 is a suggested mechanism in the development and increase in severity of congestive heart failure; the reduction may be aggravated by concurrent medical therapy (eg beta-blockers and statins) that can suppress endogenous CoQ10 synthesis
  • Current evidence indicates that CoQ10 supplementation may be an option in the management of heart failure
  • Q-SYMBIO trial, a double-blind trial on CoQ10 as adjunctive therapy of chronic heart failure, found that supplementation with CoQ10 was safe and resulted in heart failure symptom improvement and reduction in major adverse cardiovascular events and mortality
  • CoQ10 comes in a reduced (Ubiquinol) and an oxidized (Ubiquinone) form
  • Absorption is maximized if CoQ10 is administered with fats
  • A physiologic decline in CoQ10 levels and a decrease in CoQ10-reducing capacity occur with age
    • A study showed an association between high serum levels of Ubiquinol and low serum levels of NT-proBNP, an indicator of disease severity for chronic heart failure, in healthy elderly subjects who received Ubiquinol supplementation

Non-Pharmacological Therapy

Travel

  • Discuss travels plans with the physician because patients with heart failure (HF) are at increased risk of deep venous thrombosis (DVT)
  • Air travel is preferred than other means of transportation, especially on long journeys
    • Long flights may predispose patients to accidental omission of medicines, edema of the lower extremities, dehydration, and DVT
    • DVT prophylaxis with a single injection of low molecular weight heparin and/or graduated compression stockings plus calf stretching during the flight are recommended
    • Pharmacotherapy may be added if there is significant risk of DVT
  • Avoid high altitude destinations of >1500 meters because of relative hypoxia

Sleep and Breathing Disorders

  • Patients with symptomatic HF usually have sleep-related breathing disorders (eg central or obstructive sleep apnea)
  • Weight loss in obese patients, smoking cessation, and abstinence from alcohol are recommended to decrease the risks
  • Continuous positive airway pressure (CPAP) should be considered in polysomnograph-documented obstructive sleep apnea to improve daily functional capacity and quality of life

Depression and Mood Disorder

  • Screening for endogenous or prolonged reactive depression in patients with HF should be done following diagnosis and at periodic intervals as clinically indicated
  • Initiate appropriate pharmacotherapy and provide psychosocial support

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
13 Oct 2017
Higher circulating levels of docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) appear to be protective against incident atherothrombotic and cardioembolic strokes, respectively, according to a recent study.
Roshini Claire Anthony, 11 Oct 2017

The prevalence of resistant hypertension may be lower than expected, particularly once pseudo-resistant hypertension due to treatment nonadherence is taken into account, according to a presentation at the recent APCH 2017.

Pank Jit Sin, 07 Jan 2015

Cardiovascular diseases (CVD) have been the main cause of death in the Malaysian population since 2007. This trend has continued, with the number of people dying from CVD-related causes increasing year on year. 

Tristan Manalac, 12 Oct 2017
Administration of a long-acting medication at the time that is most suitable for maximum patient compliance is the best approach in controlling blood pressure, said Dr. Trefor Morgan at the recently concluded 13th Asian-Pacific Congress of Hypertension (APCH 2017), held at the Suntec Singapore Convention and Exhibition Centre.